RxDoctor Payments Data

Ryan Yoder, MD

Neurology · Battle Creek, MINPI 1700994019

Payments from drug & device makers

$9,777in general payments, 2019–2025

Across 576 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$876
  • Pfizer$821
  • UCB, Inc.$660
  • Bristol Myers Squibb$617
  • SK Life Science, Inc.$566
  • plus $5K from 36 others

What the payments were for

  • Food & beverage$9,67699%
  • Education$1021%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,777 in reported general payments places this provider in the 70th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$47,443
Medicare patients
275
Services billed
454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe147$112,743
GocovriAmantadine Hcl13$42,112
Nurtec OdtRimegepant Sulfate41$40,072
Emgality SyringeGalcanezumab-Gnlm25$23,138
RytaryCarbidopa/Levodopa19$20,660
Emgality PenGalcanezumab-Gnlm25$19,675
XcopriCenobamate14$17,038
BriviactBrivaracetam12$16,755
Ajovy SyringeFremanezumab-Vfrm21$14,703
Carbidopa-LevodopaCarbidopa/Levodopa255$7,239
Divalproex Sodium20$6,521
Rivastigmine16$4,085
Memantine Hcl123$3,842
Carbamazepine ErCarbamazepine18$3,085
Lamotrigine100$2,515

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$821$40,07241 claims
Amneal Pharmaceuticals LLCRytary$14$20,66019 claims
SK Life Science, Inc.Xcopri$566$17,03814 claims
UCB, Inc.Briviact$660$16,75512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 652 neurology providers in Michigan.

Other neurology in Battle Creek

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →